CardioInsight chairman & CEO Steve Arless resigns, to be replaced by 2-man "office of the president"
Zeltiq
J&J veteran Donald Casey takes helm of medical segment at Cardinal Health | Personnel Moves
Cardinal Health appointed Donald Casey Jr. to lead its $9 billion medical products and services division, effective next week.
Imaging3 loses director, president & COO Sohn | Personnel Moves
Imaging3 (OTC:IMGG) president & COO resigned "to pursue other interests," according to a regulatory filing, leaving the mobile fluoroscopy device maker without a replacement.
Sohn, whose resignation was effective March 31, was still listed on Imaging3’s website today. The company agreed to pay out $9,100 in severance, according to the filing.
Ex-Stryker CEO MacMillan earned $9.5M in 2011 | Personnel Moves
Stryker’s (NYSE:SYK) former CEO, Stephen MacMillan, walked away from a pay package worth more than $9.5 million last year, SEC filings show.
MacMillan’s pay included more than $1.3 million in salary, $3.6 million in stock awards and $3.1 million in option awards in 2011, doubling the $4.7 million he received in 2010.
Biolase CEO Pignatelli touts $1 salary | Earnings Roundup
Biolase Technology (NSDQ:BLTI) CEO Federico Pignatelli agreed to another year at a $1 salary as the dental laser maker met Wall Street’s 4th-quarter forecast with a whopping 35% top-line bump.
Pignatelli set his annual pay package at $1 and 35,000 shares of BLTI stock when he took the role of vice chairman in July 2010, a month after he was terminated as president, SEC filings show.
St. Jude Medical rebounds after “Greek tragedy” | Wall Street Beat
Shares of St. Jude Medical (NYSE:STJ) clawed back some of the value lost yesterday in what 1 waggish analyst termed a “Greek tragedy.”
STJ shares closed down 3.3% yesterday at $39.96 when the company revealed a $56 million writedown after a Greek distributor failed to pay up for an estimated 2 years worth of sales.
GMI Ratings adds Boston Scientific to risky bet list | Wall Street Beat
A rating agency specializing in evaluating risky investments added Boston Scientific (NYSE:BSX) to its "Risk List," citing the ongoing fallout from its ill-starred Guidant buyout, its accounting and governance practices and how it pays its executives.
Heart docs claim harassment for exposing poor patient care | Legal News
A group of California cardiologists filed a lawsuit against Santa Clara Valley Medical Center, alleging that they were harassed out of their jobs after they complained about a pattern of compromised patient safety at the hospital.
The plaintiffs are led by echocardiographer Dr. Geeta Singh and cardiothoracic surgeon Dr. Kai Ihnken, with 2 additional cardiologists named alongside them in the lawsuit.
Goldman pans Wall Street’s med-tech estimates
Wall Street’s overall take on sales and earnings forecasts for medical device makers this year is too high, according to Goldman Sachs (NYSE:GS) analyst David Roman, who sees The Street’s 4th-quarter top-line estimates as split evenly among companies with upside and downside.
Boston University lands $13.6M to study cancer detection tools | Funding Roundup
Boston University School of Medicine landed a $13.6 million grant from the U.S. Defense Dept. lung cancer research program to study technologies focused on the early detection of lung cancer.
The five-year study, the Detecting Early Lung Cancer Among Military Personnel consortium, will focus on veterans and active military personnel at number of military hospitals and VA medical centers across the country.
Smoking rates are 50 percent higher in military populations than civilian populations and veterans are between 25 and 75 percent more likely to develop lung cancer than non-veterans, according to BU.
Zeltiq handed FDA clearance for fat reduction device
Zeltiq landed 510(k) clearance from the Food & Drug Administration for its fat reducing device.
The Pleasanton, Calif. based medical device developer’s CoolSculpting system works by cooling flabby tissue and leaving the skin’s surface unaffected, the company said.